Related Experiment Video
Updated: May 17, 2026
05:44
Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
Published on: October 13, 2023
Moyamoya disease can masquerade as multiple sclerosis.
Leslie J Dorfman1, Nancy J Fischbein, Joslyn I Woodard
1Departments of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. ldorfman@stanford.edu
The Neurologist
|November 2, 2012
Summary
Moyamoya disease (MM) can be misdiagnosed as multiple sclerosis (MS), delaying crucial treatment. Early identification of MM through distinct clinical and radiologic features is vital for timely intervention.
Area of Science:
- Neurology
- Vascular Neurology
- Neuroimmunology
Background:
- Moyamoya disease (MM) is a rare cerebrovascular disorder affecting arterial circulation.
- Multiple sclerosis (MS) is a common immune-mediated demyelinating disease.
- Both MM and MS can present with overlapping symptoms and imaging findings in young adults.
Observation:
- Diagnostic confusion between MM and MS can lead to significant treatment delays.
- Case studies reveal delays ranging from months to nearly two decades.
- This overlap necessitates careful differential diagnosis.
Findings:
- MM can mimic MS, leading to delayed diagnosis and treatment.
- Specific clinical and radiological features differentiate MM from MS.
- Prompt differentiation is key to effective management.
Implications:
- Early consideration of MM in MS differentials is crucial.
- Accurate diagnosis ensures timely and appropriate treatment for MM.
- Distinguishing MM from MS optimizes patient outcomes and treatment efficacy.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:26Transient Ischemic Attack l: Introduction
A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...